Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study

NCT01385319 Phase 3 UNKNOWN

To prospectively evaluate in a multicenter open label trial whether the use of zotarolimus-eluting ENDEAVOR Stent implantation in patients at low restenosis or at high bleeding or thrombotic risk will decrease the incidence of 12-month major adverse cardiac events (MACE) including overall death, any myocardial infarction (MI) or any target vessel revascularization (TVR).

Details

Lead sponsor	Marco Valgimigli
Phase	Phase 3
Status	UNKNOWN
Enrolment	1606
Start date	2011-06
Completion	2017-12

Conditions

• Coronary Artery Disease

Interventions

• Bare metal stent implantation
• zotarolimus eluting stent

Primary outcomes

• MACE — 12 months
  Major adverse cardiovascular events including death for any cause, non-fatal myocardial infarction or target vessel revascularisation

Countries

Hungary, Italy, Portugal, Switzerland